Updated: March 10, 2010
 
 Options
 
Advanced
     This area of the site
     requires the Adobe
     Acrobat Reader and
     a Media Player.
     Click below to
     download the
     software now.


Download the Adobe Acrobat reader.

Download the Windows Media Player

Download the RealOne Player

Download the QuickTime player

 
 
Conference highlights and audio downloads.
Release Date   Meeting Title
Dec 16 2009
Advancing Knowledge and Tackling Important Clinical Questions in Atrial Fibrillation Management
CME highlights of a VBWG Town Hall exploring the new era in atrial fibrillation management
Dec 15 2009
Orlando, Florida
Advancing Knowledge and Tackling Important Clinical Questions in Atrial Fibrillation Management
CME newsletter of a VBWG Town Hall exploring the new era in atrial fibrillation management
Dec 15 2009
Chicago, Illinois
Undiagnosed Type 2 Diabetes and Microalbuminuria
George L. Bakris, MD, FASN, FAHA
The University of Chicago – Pritzker
  School of Medicine
Chicago, Illinois
Dec 14 2009
Central BP Measurement: Is clinical practice implementation near?
Data Alert CME
Dec 10 2009
San Antonio, Texas
Progressive Visual Loss in Type 2 Diabetes
Robert J. Chilton, DO
University of Texas Health Science Center
San Antonio, Texas
Dec 02 2009
Buffalo, New York
Undiagnosed Type 2 Diabetes and Long-term CV Risk Reduction
Paresh Dandona, MBBS, Dphil, FRCP,
  FACP, FACC, FACE
University at Buffalo
  The State University of New York
Buffalo, New York
Nov 02 2009
Boston, Massachusetts
Role of Platelet Reactivity in Science and Practice
Jane E. Freedman, MD
Professor of Medicine and Pharmacology
Boston University School of Medicine
Boston, Massachusetts
Aug 25 2009
San Francisco, California
Blood Pressure Control in the Age of Combination Therapy in CV Risk Reduction: What Have We ACCOMPLISHed?
George L. Bakris, MD, FASN, FAHA
The University of Chicago –
Pritzker School of Medicine
Chicago, Illinois
Jul 22 2009
San Antonio, Texas
Diabetic Retinopathy, Clinical Pearls for Cardiologists
Robert J. Chilton, DO, FACC, FACP
Professor of Medicine
The University of Texas Health Science Center
Jul 22 2009
Philadelphia, Pennsylvania
Peripheral Artery Disease and Diabetes Mellitus: Pathology and Emerging Treatment
Emile R. Mohler III, MD, FACC, FSVM
Associate Professor of Medicine
University of Pennsylvania School of Medicine
Jul 21 2009
Orlando, Florida
Glucose Control and Complications: New Trials Modify the Paradigm
William C. Duckworth, MD
University of Arizona College of Medicine
Phoenix, Arizona
Jul 06 2009
New York, New York
The Electrophysiologist’s Perspective on AF Management
James A. Reiffel, MD, FACC, FAHA, FACP, FHRS
Columbia University College of Physicians and Surgeons
New York, New York
Jun 08 2009
AHA, May 2009
Suppression of Atrial Fibrillation: Focus on Atrial-Selective Strategies
A. John Camm, MD, FACC, FESC, FAGC, FAHA, FRCP
Professor of Clinical Cardiology
Head of Cardiac and Vascular Sciences
St. George’s University of London
London, United Kingdom
Jun 03 2009
Boston, Massachusetts
Physiologic Basis of Hyperglycemia in Macro- and Microvascular Disease
Richard W. Nesto, MD, FACC, FAHA
Lahey Clinic Medical Center
Burlington, Massachusetts
May 15 2009
Durham, North Carolina
Selective Inhibition of Factor Xa in ACS: APPRAISE
John H.P. Alexander, MD, MHSc, FACC
Duke Clinical Research Institute
Durham, North Carolina
Mar 30 2009
AHA, November 2008
The Current Status of Putative Surrogate Endpoints
Robert M. Califf, MD, MACC
Duke University School of Medicine
Durham, North Carolina
Dec 15 2008
Boston, Massachusetts
Innovative Strategies in Cardiometabolic Risk Reduction
Caroline M. Apovian, MD, FACP, FACN
Boston University School of Medicine
Boston, Massachusetts
Nov 19 2008
US Chapter Meeting
Effect of Progenitor Cell Mobilization on Endothelial Function and Symptoms in Patients with PAD
Arshed A. Quyyumi, MD
Emory University School of Medicine
Atlanta, Georgia

Nov 19 2008
Atlanta, Georgia
Antithrombotic Therapy in PCI: Guidelines and Beyond
Spencer B. King III, MD, MACC, FACP, FESC, FSCAI
Cleveland Clinic Foundation
Cleveland, Ohio
Oct 09 2008
Buffalo, New York
Anti-inflammatory and Anti-atherogenic Effects of Insulin
Paresh Dandona, MBBS, Dphil, FRCP,
FACP, FACC, FACE
University at Buffalo
The State University of New York
Buffalo, New York
Sep 24 2008

Implications of the ENHANCE Trial for Practicing Cardiologists

Steven E. Nissen, MD, MACC
Cleveland Clinic Foundation
Cleveland, Ohio
Sep 19 2008
Philadelphia, Pennsylvania

Psychosocial Impact of Obesity: Evaluation and Implications for Managing CVD

Thomas A. Wadden, PhD
University of Pennsylvania
School of Medicine
Philadelphia, Pennsylvania
Aug 26 2008

Myocardial Ischemic Memory Imaging with Molecular Echocardiography

Jonathan R. Lindner, MD
Oregon Health and Science University
Portland, Oregon
Aug 11 2008
Atlanta, Georgia
Hyperglycemia and ACS: Effects on Myocardial Energetics and Blood Flow
Ori Ben-Yehuda, MD, FACC
University of California, San Diego
Jul 02 2008
Milwuakee, Wisconsin
Cannabinoid Receptor Blockade as a Pharmacotherapy for Weight Loss: An Update
Cecilia J. Hillard, PhD
Medical College of Wisconsin
Milwaukee, Wisconsin
Jun 26 2008
Atlanta, Georgia

WISE Update: Women at High Risk for Reduced CV Survival

Leslee J. Shaw, PhD
Emory University School of Medicine
Jun 05 2008
Boston, Massachusetts

Nanoparticle Imaging of Macrophages in Atherosclerotic Lesions

Peter Libby, MD, FACC
Harvard Medical School
Jun 05 2008

The Evolving Landscape of Transcatheter Valve Replacement/Repair

Peter C. Block, MD, FACC
Emory University School of Medicine
Atlanta, Georgia
May 30 2008
Orlando, Florida
Mechanisms of RAAS Receptors in Cardioprotection
Arshed A. Quyyumi, MD, FRCP, FACC
Emory University School of Medicine
May 22 2008
Durham, North Carolina

Implications of the ENHANCE Trial for Practicing Cardiologists

Robert M. Califf, MD, MACC
Duke University Medical Center
May 19 2008
VBWG 2008 US Chapter Meeting held at the ACC

Anticoagulation for Stroke Prevention in Patients

Jeffrey L. Anderson, MD, FACC, FAHA, MACP
University of Utah School of Medicine
May 12 2008
Cleveland, Ohio

Rationale for ACE Inhibitor — ARB Combination Therapy

Ileana L. Piña, MD, FACC
Case Western Reserve University
Apr 28 2008
Gainesville, Florida

Leading the Way in Cardiovascular Regenerative Medicine

Carl J. Pepine, MD, MACC
University of Florida College of Medicine
Mar 25 2008
Orlando, Florida
Global CV Risk Management: Is it Practical?
JoAnne M. Foody, MD, FACC, FAHA
Harvard Medical School
Mar 18 2008
San Francisco, California
Lifestyle Modification and the Patient with Complicated Hypertension
C. Noel Bairey Merz, MD
Cedars-Sinai Medical Center
Mar 07 2008
Orlando, Florida
Progress and Promise in RAAS Blockade
Carl J. Pepine, MD, MACC
University of Florida College of Medicine
Feb 15 2008
Chicago, Illinois
Parenteral Treatments in Acute Hypertension
Jerrold Levy, MD, FAHA
Emory University School of Medicine
Jan 28 2008
New York, NY
Understanding Chronic Ischemic Heart Disease Today
Robert L. Wilensky, MD, FACC
University of Pennsylvania Health System
Dec 26 2007
Irving, CA
Risk Stratification in Patients with Chronic Myocardial Ischemia
William S. Weintraub, MD, FACC
Christiana Care Health System
Nov 27 2007
Irving, TX
Understanding Chronic CAD: Flow-Limiting Obstruction vs Vulnerable Plaque
Peter H. Stone, MD, FACC, FAHA
Harvard Medical School
Nov 15 2007
Dallas, TX
Insights on the Interaction of Antiarrhythmia Therapy and Ischemia
Peter R. Kowey, MD, FACC
Jefferson Medical College
Oct 25 2007
Dallas, TX
Ischemic Heart Disease Risk Management in Women: Recent Evidence
C. Noel Bairey Merz, MD, FACC
Cedars-Sinai Medical Center
Oct 22 2007
Orlando, FL
Pathophysiology of Atherogenic Dyslipidemia
Ronald M. Krauss, MD
University of California, Berkeley
Oct 10 2007
Irving, Texas
Winning CV and Metabolic Parameters
Carl J. Pepine, MD, MACC
University of Florida College of Medicine
Sep 26 2007
Houston, TX
Intensive Glycemic Control and CV Risk Reduction
Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP
William Beaumont Hospital
Sep 19 2007
Irving, Texas
Angina and Ischemia Reduction: Trial Update
Benjamin M. Scirica, MD, MPH
Harvard Medical School
Sep 12 2007
Houston, Texas
Impact of Hyperglycemia at the Vessel Wall
Ajay Chaudhuri, MBBS, MRCP, FACE
Diabetes - Endocrinology Center of Western New York
Aug 15 2007
New York, New York
Assessing Global Cardiovascular and Diabetes Risk: Targeting Abdominal Adiposity
Robert E. Heinig, MD
Rochester General Hospital
Aug 08 2007
New York, New York
Intensive Glycemic Control and CV Risk Reduction
Stuart W. Zarich, MD, FACC, FASE
Yale University School of Medicine
Aug 01 2007
Orlando, Florida
Clinical Imperatives for Treating ACS Patients with Diabetes
Darren K. McGuire, MD, MHSc, FACC
Parkland Health and Hospital System
Jul 25 2007
Orlando, Florida
Glycemic Control and Patient Outcomes: Clinical Trial Overview
Robert E. Heinig, MD
Rochester General Hospital
Jul 18 2007
Atlanta, Georgia
Recent Insights on Abdominal Adiposity and CV Risk
Ori Ben-Yehuda, MD, FACC
University of California, San Diego
Jul 12 2007
Orlando, Florida
Prognostic Importance of Hyperglycemia in Coronary Events
JoAnne M. Foody, MD, FACC
Yale University School of Medicine
Jul 03 2007
Detroit, Michigan
Role of Glucose Control in CV Risk Modification
Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP
William Beaumont Hospital
Jun 27 2007
Orlando, Florida
Hyperglycemia in Acute Coronary Syndromes
Ira J. Goldberg, MD
Columbia University College of Physicians and Surgeons
Jun 20 2007
Orlando, Florida
Residual CV Risk and Future Treatment Strategies
Deepak L. Bhatt, MD, FACC, FESC, FSCAI, FACP
Cleveland Clinic Lerner College of Medicine
Jun 13 2007
Chicago, Illinois
Assessing Global Cardiovascular and Diabetes Risk: Targeting Abdominal Adiposity
Howard S. Weintraub, MD, FACC
New York University School of Medicine
Jun 06 2007
Orlando, Florida
Implications of CB1 Blockade for the Cardiologist
Andrew P. Selwyn, MD, FRCP, FACC
Harvard Medical School
May 30 2007
Orlando, Florida
Impact of Insulin Resistance on Cardiometabolic Risk
Theodore Mazzone, MD, FACP, FAHA
University of Illinois College of Medicine
May 21 2007
New Orleans, Louisiana
The RUTH Trial: Estrogen Receptor Modulation and CV Events
Elizabeth L. Barrett-Connor, MD
University of California, San Diego,
School of Medicine
May 16 2007
Orlando, Florida
Adiposity in Cardiovascular Risk Reduction
Jorge Plutzky, MD, FACC, FAHA
Harvard Medical School
May 09 2007
New Orleans, Louisiana
The New NHLBI CV Cell Therapy Research Network
Robert D. Simari, MD
Mayo Clinic College of Medicine
May 02 2007
Nashville, Tennessee
Reducing Cardiovascular Morbidity and Mortality Through RAAS Modulation: New Trial Data
Eva M. Lonn, MD, MSc, FRCPC, FACC
Hamilton Health Sciences
Apr 25 2007
    Short Hills, New Jersey
Inhibiting Angiotensin II at the Vessel Wall: Impact on Atherosclerosis
Robert L. Wilensky, MD, FACC
University of Pennsylvania School of Medicine
Apr 18 2007
New Orleans, Louisiana
The Cardiovascular Disease Continuum: Trends, Lessons, and a Look to the Future
Victor J. Dzau, MD
Duke University Medical Center
Apr 12 2007
Gaithersburg, Maryland
Long-Term Effects on Arterial Healing with DES
Renu Virmani, MD, FACC
CVPath Institute, Inc.
Mar 29 2007
Royal Oak, Michigan
Clinical Imperatives for Treating Patients with Diabetes
Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP
William Beaumont Hospital
Mar 07 2007
Chicago, Illinois
Vascular Protection and CB1 Blockade:
Evolving Data

Jean-Pierre Després, PhD, FAHA
Laval Hospital Research Centre
Laval University
Feb 28 2007
Chicago, Illinois
The Apelin System and Potential Therapeutic Applications
Douglas E. Vaughan, MD, FACC
Vanderbilt University Medical Center
Feb 13 2007
Québec City, Québec, Canada
ACE Inhibition and Vascular Disease:
Recent Insights

Gilles R. Dagenais, MD
Québec Heart Institute
Laval University
Jan 24 2007
Seattle, Washington
New Therapeutic Options for the Treatment of Chronic Angina
David A. Morrow, MD, MPH, FACC, FAHA
Harvard Medical School
Jan 17 2007
Orlando, Florida
Estrogen and RAAS: New Mechanistic Insights
Paula J. Harvey, MD, PhD
University of Toronto
Jan 10 2007
Irving, Texas
A Diabetes Outcome Prevention Trial
Steven M. Haffner, MD, MPH, FACP
University of Texas Health Science Center
Jan 03 2007
Toronto, Ontario, Canada
Do Angiotensin Receptor Blockers Increase the Risk of Myocardial Infarction?
Martin H. Strauss, MD, FRCPC, FACC
North York General Hospital
Dec 20 2006
La Jolla, California
Should the Use of Drug Eluting Stents Be Routine in Patients with Acute Coronary Syndromes?
Jeffrey J. Popma, MD
Harvard Medical School
Dec 11 2006
Chicago, Illinois
Update on Efficacy in Acute Myocardial Infarction with DES
Frans Van de Werf, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium
Dec 07 2006
Chicago, Illinois
Long-Term Effects on Arterial
Healing with DES

Renu Virmani, MD, FACC
CVPath Institute, Inc.
Nov 30 2006
Chicago, Illinois
Imaging Modalities for Stem Cell Therapy
Joseph C. Wu, MD, PhD
Stanford University School of Medicine
Nov 28 2006
Chicago, Illinois
The Promise of Stem Cell Therapies
Douglas W. Losordo, MD
Northwestern University Medical School
Nov 21 2006
Chicago, Illinois
Scientific and Mechanistic Rationale for the MERLIN Study
Bernard R. Chaitman, MD, FRCPC, FACC, FAHA
Saint Louis University School of Medicine
Nov 17 2006
Chicago, Illinois
Gene Analysis of Cardiac Transplanted Cells
Amit N. Patel, MD, MS
University of Pittsburgh Medical Center
Nov 14 2006
Chicago, Illinois
Qualitative Changes of HDL in Metabolic
Syndrome – Impact on Vasoprotective Properties

Ulf Landmesser, MD
Medizinische Hochschule Hannover
Nov 01 2006
Houston, Texas
Vascular Consequences of Diabetes and Insulin Resistance
Darren K. McGuire, MD, FACC, FACP
University of Texas Southwestern Medical Center at Dallas
Oct 16 2006
Orlando, Florida
­Vascular Biology: Progress and Promise in Cardiovascular Disease Management
Carl J. Pepine, MD, MACC
University of Florida College of Medicine
Oct 11 2006
Marina del Rey, California
CV Risk Reduction, Diabetes Prevention, and TZDs
Jeffrey L. Probstfield, MD, FACC, FACP
University of Washington School of Medicine
Sep 18 2006
New York, New York
Placing Renal Disease In Perspective
Gerald B. Appel, MD
Columbia University College of Physicians and Surgeons
Sep 08 2006
New York, New York
The Diabetes Pandemic: Urgent Need for Prevention
Jeffrey L. Probstfield, MD, FACC, FACP
University of Washington School of Medicine
Aug 09 2006
San Francisco, California
Clinical Implications of Insulin Resistance
Willa A. Hsueh, MD
David Geffen School of Medicine at UCLA
Aug 02 2006
Philadelphia, Pennsylvania
Clinical Imperatives for Treating Patients with Diabetes
Peter N. Weissman, MD, FACE, FACP
University of Miami School of Medicine
Jul 21 2006
Atlanta, Georgia
Vascular Consequences of Diabetes and Insulin Resistance
Andrew P. Selwyn, MD, FRCP, FACC
Harvard Medical School
Jul 12 2006
Houston, Texas
Practical Considerations in the Management of Patients with Chronic Ischemic Heart Disease
Robert L. Wilensky, MD, FACC
University of Pennsylvania School of Medicine
Jul 05 2006
Boston, Massachusetts
Novel Approaches in Chronic Myocardial Ischemia
Peter H. Stone, MD, FACC, FAHA
Harvard Medical School
Jun 16 2006
Marina del Rey, California
New Therapeutic Options for Treating Chronic Myocardial Ischemia
David A. Morrow, MD, MPH, FACC, FAHA
Harvard Medical School
Jun 07 2006
St. Louis, Missouri
Case-Study: Optimizing Clinical Outcomes in Myocardial Ischemia
Moderator:
Bernard R. Chaitman, MD, FRCPC, FACC, FAHA
Discussants:
Robert W. Biederman, MD, FACC, FASA
Jerome D. Cohen, MD, FACC, FACP
May 31 2006
St. Louis, Missouri
Practical Considerations in the Management of Patients with Chronic Ischemic Heart Disease
Jerome D. Cohen, MD, FACC, FACP
Saint Louis University School of Medicine
May 24 2006
Brooklyn, New York
Halting Cardiovascular Disease Progression in Patients with Multiple Risk Factors
Gerald B. Appel, MD
Columbia University College of Physicians and Surgeons
May 24 2006
New York, New York
Myocardial Ischemia: View from the Vessel Wall
Andrew P. Selwyn, MD, FRCP, FACC
Harvard Medical School
Apr 20 2006
Philadelphia, Pennsylvania
New Therapies to Improve Outcomes in Patients with Multiple CV Risks
Robert A. Vogel, MD
University of Maryland School of Medicine
Apr 20 2006
Cincinnati, Ohio
Identifying Candidates at High Risk of Cardiovascular Disease
Roy C. Blank, MD
The Presbyterian Cardiovascular Institute
Apr 12 2006
Orlando, Florida
Diabetes Pandemic: Prevention Urgently Needed
Jeffrey L. Probstfield, MD, FACC, FACP
University of Washington School of Medicine
Mar 29 2006
St. Petersburg, Florida
Contemporary Strategies for Managing Myocardial Ischemia
Bernard R. Chaitman, MD
Saint Louis University School of Medicine
Mar 21 2006
Atlanta, Georgia
Intramyocardial Transplantation of Autologous
CD34+ Cells for Intractable Angina

Douglas W. Losordo, MD
Tufts University School of Medicine
Mar 16 2006
St. Petersburg, Florida
New Mechanistic Insights in
Ischemia and Coronary Supply

Peter H. Stone, MD
Harvard Medical School
Mar 03 2006
Chicago, Illinois
Tailoring Antithrombotic Therapies
Lloyd W. Klein, MD
Rush Medical College
Mar 01 2006
Coral Gables, Florida
Negative Effects of Insulin
Resistance on the Vessel Wall

Darren K. McGuire, MD, FACC, FACP
University of Texas Southwestern
Medical Center at Dallas
Feb 24 2006
Princeton, New Jersey
Halting Cardiovascular Disease Progression in Patients with Multiple Risk Factors
Gerald B. Appel, MD
Columbia University College of Physicians and Surgeons
Feb 22 2006
Philadelphia, Pennsylvania
Antiplatelet Strategies in ACS: Clinical Trial Data
Robert L. Wilensky, MD, FACC
University of Pennsylvania School of Medicine
Feb 17 2006
Philadelphia, Pennsylvania
The Role of Platelets in Atherothrombosis
Richard C. Becker, MD
Duke University Medical Center
Feb 10 2006
La Jolla, California
The Role of Platelets in Atherothrombosis
Andrew P. Selwyn, MD, FRCP, FACC
Harvard Medical School
Feb 03 2006
Washington, DC
An Update on Therapeutic Interventions Against Platelet Activation and Aggregation
Robert P. Giugliano, MD, SM
Harvard Medical School
Feb 03 2006
Washington, DC
Early, Comprehensive Management of ACS: Perspectives on New Trial Data
William E. Boden, MD, FACC
University of Connecticut School of Medicine
Feb 03 2006
McLean, Virginia
Treatment Strategies for Halting the Progression of CVD in High Risk Patients
James R. Sowers, MD, FACE, FACP
University of Missouri-Columbia
Jan 23 2006
New York, New York
Treatment Strategies for Halting the Progression of CVD in High Risk Patients
Samuel Dagogo-Jack, MD, FRCP
University of Tennessee College of Medicine
Dec 21 2005
Washington, DC
The CRUSADE Registry: Status Report
Eric D. Peterson, MD, MPH, FACC, FAHA
Duke University Medical Center
Dec 16 2005
Orlando, Florida
Impact of Recent Clinical Trials on Optimal Lipid Goals
Robert A. Vogel, MD
University of Maryland School of Medicine
Dec 06 2005
Dearborn, Michigan
Biomarkers of Cardiovascular Disease: Traditional and Emerging Concepts
Arshed A. Quyyumi, MD, FACC, FRCP
Emory University School of Medicine
Oct 27 2005
Phoenix, Arizona
New Data and Directions in the Treatment of Coronary Artery Disease
Carl J. Pepine, MD, MACC
University of Florida College of Medicine
Oct 19 2005
St. Louis, Missouri
Should All Coronary Artery Disease Patients be Given an ACE Inhibitor?
Jerome D. Cohen, MD, FACC, FACP
Saint Louis University
Oct 06 2005
Cleveland, Ohio
Negative Effects of Insulin Resistance on the Vessel Wall
Andrew P. Selwyn, MD, FRCP, FACC
Harvard Medical School
Aug 29 2005
New York, New York
Implementing Treatment Guidelines in Clinical Practice
Robert E. Heinig, MD
University of Rochester Medical School
Aug 18 2005
Atlanta, Georgia
EUROPA in the Context of HOPE and PEACE
Willem J. Remme, MD, PhD, FESE, FACC, FAHA
Sticares Cardiovascular Research Foundation
Aug 09 2005
Chicago, Illinois
Clinical Update: Should All CAD Patients be Treated With an ACE Inhibitor?
Eva Lonn, MD, MSc, FRCPC, FACC
McMaster University
Jul 25 2005
Amelia Island, Florida
Central Role of Fat on Progression of Insulin Resistance and Cardiovascular Disease: New Data
Willa A. Hsueh, MD
University of California, Los Angeles
Jun 17 2005
Orlando, Florida
RAAS Modulation in the Atherosclerotic process: Mechanistic insights
Howard R. Horn, MD, FACC, FACP, FAHA
The University of Tennessee Health Science Center
May 12 2005
Orlando, Florida
Endothelial Dysfunction and Repair: Potential Role for Endothelial Progenitor Cells
Arshed A. Quyyumi, MD, FRCP, FACC
Emory University School of Medicine
May 06 2005
Orlando, Florida
The Mediterranean Diet: Ideal Cardiovascular Diet?
James H. O'Keefe, Jr, MD, FACC
University of Missouri - Kansas City Medical School
Mar 04 2005
Philadelphia, Pennsylvania
Vascular benefits of ACE inhibition: An update
Andrew P. Selwyn, MD
Harvard Medical School
Dec 16 2004
Philadelphia, Pennsylvania
Optimizing CAD protection: New trial data
Eva Lonn, MD, MSc, FRCPC, FACC
McMaster University
Dec 14 2004
Houston, Texas
Redefining strategies in treating diabetic dyslipidemia
James R. Sowers, MD, FACE, FACP
University of Missouri-Columbia
Dec 06 2004
Chicago, Illinois
Translating the trials: Applying evidence-based medicine to clinical practice
Elizabeth O. Ofili, MD
Morehouse School of Medicine
Nov 19 2004
New York, New York
Optimizing CAD protection: New trial data
Howard S. Weintraub, MD
New York University School of Medicine
Nov 15 2004
Coral Gables, Florida
Scientific update: LDL and RAAS: The role of oxidative stress and vascular inflammation
Arshed A. Quyyumi, MD, FRCP
Emory University School of Medicine
Nov 10 2004
Kohler, Wisconsin
Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process
Philip R. Liebson, MD, FACC, FACP, FAHA
Rush University Medical Center
Nov 01 2004
Philadelphia, Pennsylvania
The new vascular biology mandate for aggressive lipid management
Andrew P. Selwyn, MD
Harvard Medical School
Oct 14 2004
Los Angeles, California
Vulnerable patient, vulnerable plaque: New scientific insights
Arshed A. Quyyumi, MD, FRCP
Emory University School of Medicine
Oct 11 2004
New York, New York
Reassessing clinical management of heart failure: New trial data of beta-blockade and RAAS manipulation
Ileana L. Piña, MD
Case Western Reserve University
Sep 22 2004
Houston, Texas
Multifactorial intervention on macrovascular and microvascular outcomes for diabetes risk reduction: Practical insights and strategies
Vivian A. Fonseca, MD
Tulane University Health Sciences Center
Sep 21 2004
Seattle, Washington
Clinical trials update: Strategies for multiple risk interventions
C. Venkata S. Ram, MD, FACC, MACP
University of Texas Southwestern Medical Center at Dallas
Sep 10 2004
Orlando, Florida
Optimizing CAD protection: New trial data
Eva M. Lonn, MD, MSc, FRCPC, FACC
McMaster University
Aug 16 2004
New York, New York
Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process
Jerome D. Cohen, MD, FACC, FACP
Saint Louis University School of Medicine
Jun 10 2004
Hershey, Pennsylvania
Vision of a new NCEP: 2004
Robert A. Vogel, MD
University of Maryland School of Medicine
May 06 2004
Philadelphia, Pennsylvania
Role of beta-blockade in heart failure: Myths and realities
Mark E. Dunlap, MD
Case Western Reserve University
Apr 29 2004
Atlanta, Georgia
Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process
Robert L. Wilensky, MD, FACC
University of Pennsylvania School of Medicine
Apr 27 2004
Fort Lauderdale, Florida
Translating the trials: Applying evidence-based medicine to clinical practice
Thomas D. Giles, MD
Louisiana State University
Apr 14 2004
Orlando, Florida
Heart failure as an insulin resistance study: Role of RAAS manipulation and beta-blockade
Thomas D. Giles, MD
Louisiana State University Health Sciences Center
Apr 06 2004
Coral Gables, Florida
New options for anticoagulation: Focus on oral direct thrombin inhibition
Albert L. Waldo, MD
Case Western Reserve University
Mar 24 2004
Washington, DC
Clinical trials update: Role of lipid lowering in blunting the atherosclerotic process
Michael Miller, MD
University of Maryland School of Medicine
Mar 23 2004
New York,
New York
Mechanistic and scientific insights on atrial fibrillation, thrombosis, and stroke
Gerald V. Naccarelli, MD
Penn State University College of Medicine
Feb 02 2004
Coronado, California
Quality and quantity of LDL-cholesterol: New Insights
Andrew P. Selwyn, MD
Harvard Medical School
Jan 19 2004
Nashville, Tennessee
Clinical trials update: Role of early statin use in acute coronary syndromes
Robert L. Wilensky, MD
University of Pennsylvania School of Medicine
Jan 19 2004
Nashville, Tennessee
Quantity and quality of LDL- cholesterol: New insights
Douglas E. Vaughan, MD
Vanderbilt University School of Medicine
Jan 16 2004
St. Louis, Missouri
Aggressive lipid management in peri-interventional patients
Jerome D. Cohen, MD
Saint Louis University Medical Center
Jan 16 2004
St. Louis, Missouri
Clinical trials update: Role of early statin use in acute coronary syndromes
Lloyd W. Klein, MD
Rush Medical College
Sep 19 2003
New York,
New York
VBWG Regional Adjunct Faculty Meeting
  • Andrew P. Selwyn, MD
  • Jeffrey J. Popma, MD
  • James R. Sowers, MD, FACP
Jun 02 2003
Dearborn, Michigan
Interventions in Cardiology Study Group
  • James R. Sowers, MD, FACP
  • Robert L. Wilensky, MD
  • John A. Farmer, MD
Apr 26 2003
Bolton Landing, New York
VBWG Regional Adjunct Faculty Meeting
  • Andrew P. Selwyn, MD
  • C. Venkata S. Ram, MD, FACC, MACP
  • Andrew Jay Drexler, MD
Feb 22 2003
Irving, Texas
Interventions in Cardiology Study Group
  • Andrew P. Selwyn, MD
  • Robert E. Heinig, MD

Home | Literature Update | Journal Link | Resources | Meeting Highlights | Members | About VBWG | Web Links
 
Contact us at: info@vbwg.org
 
Privacy Policy
 
© 1999-2010 Medical Education Consultants, LLC